首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
【24h】

Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.

机译:碳酸酐酶抑制剂。新颖的1-取代的1,4-二氢-4-氧代-3-吡啶磺酰胺的区域选择性合成及其对人胞质同工酶I和II和跨膜癌相关同工酶IX和XII的抑制作用。

获取原文
获取原文并翻译 | 示例
           

摘要

A series of 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamide (2-16) have been synthesized and investigated as inhibitors of four isoforms of zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), that is the cytosolic ubiquitous CA I and II, and cancer-associated isozymes CA IX and XII. Against the human isozymes hCA I the new compounds showed inhibition constants in the range of 1.09-12.1 microM, against hCA II in the range of 50.5-172 nM, against hCA IX in the range of 5.2-118 nM, and against hCA XII in the range of 8.7-381 nM, respectively. Compounds 2, 3, 5-9, 11, 13 and 14 showed excellent hCA IX inhibitory efficacy, with K(I)s = 5.2-11.0 nM, being much more effective as compared to the clinically used sulfonamides AAZ, MZA, EZA, DCP and IND (K(I)s = 24-50 nM). Compounds 2, 3, 5-9, 11 and 13 were also very effective hCA XII inhibitors (K(I)s = 8.7-45.2 nM) which are comparable or more effective than those clinically used EZA and DCP (K(I)s = 22 and 50 nM), respectively.
机译:合成了一系列1-取代的1,4-二氢-4-氧代-3-吡啶磺酰胺(2-16)并作为锌酶碳酸酐酶的四种同工型的抑制剂进行了研究(CA,EC 4.2.1.1)细胞质普遍存在的CA I和II,以及与癌症相关的同功酶CA IX和XII。针对人类同工酶hCA I,新化合物在1.09-12.1 microM范围内显示抑制常数,对hCA II在50.5-172 nM范围内显示抑制常数,对hCA IX在5.2-118 nM范围内显示,以及针对hCA XII在范围分别为8.7-381 nM。化合物2、3、5-9、11、13和14表现出出色的hCA IX抑制功效,K(I)s = 5.2-11.0 nM,与临床上使用的磺酰胺类AAZ,MZA,EZA, DCP和IND(K(I)s = 24-50 nM)。化合物2、3、5-9、11和13也是非常有效的hCA XII抑制剂(K(I)s = 8.7-45.2 nM),与临床上使用的EZA和DCP(K(I)s相当或更有效) = 22和50 nM)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号